SCHEMBL5919087

SCHEMBL5919087

CC(=O)c1cc(Br)c(OCc2ccccc2)c(Br)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 5/20 0.62
THRB P10828 5/20 0.62
MAOB P27338 5/20 0.58
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
GLRA1 P23415 1/20 0.52
DHODH Q02127 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MAOA P21397 1/20 0.50
ESR1 P03372 1/20 0.50
NR3C1 P04150 1/20 0.50
PGR P06401 1/20 0.50
NR3C2 P08235 1/20 0.50
AR P10275 1/20 0.50
NR1H4 Q96RI1 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29108936 0.87 THRA (0.66) THRATHRBSMN1; SMN2LMNAHPGD
SCHEMBL21408252 0.85 LMNA (0.74) THRATHRBSMN1; SMN2LMNAHPGD
SCHEMBL5918942 0.84 KDM4E (0.60) THRATHRBMAOBSMN1; SMN2LMNA
SCHEMBL3237857 0.84 MAOB (0.55) THRATHRBMAOBSMN1; SMN2MAOA
SCHEMBL2343079 0.83 MAOB (0.59) MAOBSMN1; SMN2LMNAHPGDGLRA1
SCHEMBL17971071 0.83 LMNA (0.75) MAOBSMN1; SMN2LMNAHPGDGLRA1
SCHEMBL4784102 0.83 MAOB (0.59) MAOBSMN1; SMN2LMNAHPGDGLRA1
SCHEMBL6949611 0.82 MAOB (0.59) MAOBSMN1; SMN2LMNAHPGDMAOA
SCHEMBL6448529 0.81 THRA (0.56) THRATHRBMAOBSMN1; SMN2DHODH
SCHEMBL18480024 0.80 PKM (0.50) MAOBSMN1; SMN2LMNAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060287356-A1 dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders IYENGAR RAJESH R 2006-12-21 US disclosed
US-7119205-B2 Thienopyridones as AMPK activators for the treatment of diabetes and obesity ABBOTT LABORATORIES (US) 2006-10-10 US disclosed
US-20050038068-A1 Thienopyridones as AMPK activators for the treatment of diabetes and obesity ABBVIE INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287356-A1 dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders GPR119, FABP4, ADIPOR1 THRA 841/4885THRB 804/4885MAOB 3529/4885
US-20050038068-A1 Thienopyridones as AMPK activators for the treatment of diabetes and obesity PRKAG1, PRKAG3, PRKAG2 THRA 89/4885THRB 118/4885MAOB 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.